Mick Ruxin

Dr. Ruxin is now the President, CEO, and Director of Theralink Technologies and had initially been a strategic advisor to the Company starting in December 2017. Previously Dr. Ruxin was the Chairman, CEO, and Founder of Global Med Technologies, Inc. (GLOB).

He grew GLOB from a foundational concept to an international medical software company, specializing in FDA-approved software, with specific diagnostic capabilities, and serving over 30 countries on 4 continents. Under his leadership, GLOB had its initial financing, public offering, and subsequent follow-on financings.

Dr. Ruxin also founded PeopleMed, Inc., GLOB's validation and chronic disease management software subsidiary. In addition, he conceived and executed the acquisition and financing of Inlog, a French software company serving the EU, becoming the Directeur General and responsible for European Operations, and eDonor, a US-based regulated software company serving domestic and international blood donor centers.

Prior to Dr. Ruxin engineering the sale of GLOB to an NYSE company, Haemonetics Corp. (HAE), he led his team to national prominence by being awarded the #1 position in quality of product and customer service against billion-dollar software companies, rated by an industry-respected, independent software rating service.

After GLOB’s acquisition by Haemonetics, Dr. Ruxin was asked to stay with the company through the transition. Dr. Ruxin was on the Executive Management Team (EMT) at Haemonetics for approximately 6 months after the merger. The EMT was responsible for diagnostic strategies and identified domestic and international software opportunities for the Company.

Before founding Global Med Technologies, Dr. Ruxin founded and was President and CEO of DataMed International, Inc. (DMI), a private, international drugs abuse management company (from 1989-1997). DMI’s clients included FedEx, International Multi-Foods, Los Alamos National Laboratories, Chevron, ConAgra, Nestles, and AT&T, among over 500 other companies.